ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Theman
|
887 |
353K |
1 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
887
|
353K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Theman
|
72 |
21K |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
72
|
21K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Theman
|
27K |
13M |
7 |
03/07/24 |
03/07/24 |
ASX - By Stock
|
27K
|
13M
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
|
|
Theman
|
42 |
11K |
2 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
42
|
11K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
Theman
|
17 |
4.6K |
0 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
17
|
4.6K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
Theman
|
17 |
4.6K |
2 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
17
|
4.6K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
Theman
|
17 |
4.6K |
2 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
17
|
4.6K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
Theman
|
284 |
81K |
1 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
284
|
81K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Dr Rebecca McQualter appointed COO
|
|
Theman
|
14 |
6.4K |
9 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
14
|
6.4K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Investor Webinar - MAST Study Update
|
|
Theman
|
228 |
97K |
29 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
228
|
97K
|
29
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial
|
|
Theman
|
56 |
20K |
8 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
56
|
20K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: FDA clearance of IND for CHM 2101
|
|
Theman
|
75 |
23K |
0 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
75
|
23K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: FDA clearance of IND for CHM 2101
|
|
Theman
|
75 |
23K |
0 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
75
|
23K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: FDA clearance of IND for CHM 2101
|
|
Theman
|
75 |
23K |
0 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
75
|
23K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: FDA clearance of IND for CHM 2101
|
|
Theman
|
75 |
23K |
2 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
75
|
23K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial
|
|
Theman
|
75 |
27K |
0 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
75
|
27K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $10 million
|
|
Theman
|
99 |
33K |
4 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
99
|
33K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $10 million
|
|
Theman
|
99 |
33K |
8 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
99
|
33K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial
|
|
Theman
|
75 |
27K |
5 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
75
|
27K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Annual Report to shareholders
|
|
Theman
|
9 |
4.2K |
1 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
9
|
4.2K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
CHM-The only ASX listed CAR-T comp with 2/3 human trials
|
|
Theman
|
13 |
6.6K |
3 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
13
|
6.6K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Appoints Dr John Byon as SVP Clinical Development
|
|
Theman
|
63 |
26K |
5 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
63
|
26K
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Public Relations - IMU
|
|
Theman
|
35 |
16K |
15 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
35
|
16K
|
15
|
|
ASX - By Stock
|
IMU |
Re:
This is getting serious
|
|
Theman
|
230 |
88K |
15 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
230
|
88K
|
15
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
Theman
|
11 |
2.9K |
1 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
11
|
2.9K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
Theman
|
11 |
2.9K |
2 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
11
|
2.9K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Clinical Trials
|
|
Theman
|
16 |
7.7K |
3 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
16
|
7.7K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Appoints Dr Weitzman Interim Chief Medical Officer
|
|
Theman
|
110 |
44K |
2 |
18/07/23 |
18/07/23 |
ASX - By Stock
|
110
|
44K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Why the land mines?
|
|
Theman
|
8 |
2.5K |
4 |
26/06/23 |
26/06/23 |
ASX - By Stock
|
8
|
2.5K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
Theman
|
7 |
2.7K |
4 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
7
|
2.7K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: SPP offer documents issued to shareholders
|
|
Theman
|
14 |
6.2K |
5 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
14
|
6.2K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
Theman
|
380 |
181K |
3 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
380
|
181K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
Theman
|
138 |
46K |
2 |
15/05/23 |
15/05/23 |
ASX - By Stock
|
138
|
46K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPP
|
|
Theman
|
20 |
7.4K |
7 |
15/05/23 |
15/05/23 |
ASX - By Stock
|
20
|
7.4K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Theman
|
455 |
166K |
0 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
455
|
166K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Theman
|
455 |
166K |
1 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
455
|
166K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
CHM board Please delist from asx and transfer to US
|
|
Theman
|
5 |
2.8K |
4 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
5
|
2.8K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Theman
|
13 |
4.4K |
0 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
13
|
4.4K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Completion of Viral Vector Manufacturing for Phase 1 trial
|
|
Theman
|
16 |
6.6K |
3 |
17/04/23 |
17/04/23 |
ASX - By Stock
|
16
|
6.6K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM to host CAR T Cell Therapies Educational Webinar
|
|
Theman
|
13 |
5.5K |
1 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
13
|
5.5K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM to host CAR T Cell Therapies Educational Webinar
|
|
Theman
|
13 |
5.5K |
2 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
13
|
5.5K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM to host CAR T Cell Therapies Educational Webinar
|
|
Theman
|
13 |
5.5K |
3 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
13
|
5.5K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Theman
|
887 |
353K |
5 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
887
|
353K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Theman
|
887 |
353K |
1 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
887
|
353K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Positive pre-IND meeting with FDA for Phase 1 CAR T study
|
|
Theman
|
17 |
5.0K |
4 |
21/03/23 |
21/03/23 |
ASX - By Stock
|
17
|
5.0K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
Theman
|
138 |
46K |
3 |
20/03/23 |
20/03/23 |
ASX - By Stock
|
138
|
46K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Appendix 4D and Half Year Report
|
|
Theman
|
5 |
2.0K |
0 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
5
|
2.0K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVE
|
|
Theman
|
35 |
12K |
1 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
35
|
12K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVE
|
|
Theman
|
35 |
12K |
2 |
14/02/23 |
14/02/23 |
ASX - By Stock
|
35
|
12K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Theman
|
887 |
353K |
4 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
887
|
353K
|
4
|
|